Sheng Yang

发表

Event-free survival at 24 months is a robust surrogate endpoint for long-term survival in pediatric, adolescent, and adult T cell lymphoblastic lymphoma

Yuankai Shi, P. Liu, Jian-liang Yang, 2020, Annals of Hematology.

Ramosetron versus Ondansetron in the Prevention of Chemotherapy-Induced Gastrointestinal Side Effects: A Prospective Randomized Controlled Study

P. Liu, Yuankai Shi, Sheng Yang, 2007, Chemotherapy.

Enhancement of the International prognostic index with β2-microglobulin, platelet count and red blood cell distribution width: a new prognostic model for diffuse large B-cell lymphoma in the rituximab era

P. Liu, Jian-liang Yang, Sheng Yang, 2022, BMC cancer.

The pretreatment platelet count predicts survival outcomes of diffuse large B-cell lymphoma: An analysis of 1007 patients in the rituximab era.

P. Liu, Yuankai Shi, Jian-liang Yang, 2021, Leukemia research.

Molecular profiling of Chinese R‐CHOP treated DLBCL patients: Identifying a high‐risk subgroup

P. Liu, Yuankai Shi, Biao Liu, 2020, International journal of cancer.

Prognostic Nomogram and Predictive Factors in Refractory or Relapsed Diffuse Large B-Cell Lymphoma Patients Failing Front-Line R-CHOP Regimens

P. Liu, Yuankai Shi, Jian-liang Yang, 2020, Journal of Cancer.

A prognostic nomogram constructed for relapsed or refractory diffuse large B‐cell lymphoma patients

P. Liu, Yuankai Shi, Jian-liang Yang, 2019, Asia-Pacific journal of clinical oncology.

Systemic chemotherapy followed by locoregional definitive intensity-modulated radiation therapy yields prolonged survival in nasopharyngeal carcinoma patients with distant metastasis at initial diagnosis

P. Liu, Jian-liang Yang, Sheng Yang, 2015, Medical Oncology.

Results of the phase IIa study to evaluate the efficacy and safety of rezivertinib (BPI-7711) for the first-line treatment of locally advanced or metastatic/recurrent NSCLC patients with EGFR mutation from a phase I/IIa study

T. Wang, Yanqiu Zhao, Jianying Zhou, 2023, BMC Medicine.

Co‐mutational assessment of circulating tumour DNA (ctDNA) during osimertinib treatment for T790M mutant lung cancer

X. Yi, P. Liu, Y. Guan, 2019, Journal of cellular and molecular medicine.

Combination TS‐1 plus EGFR‐tyrosine kinase inhibitors (TKIs) for the treatment of non‐small cell lung cancer after progression on first‐line or further EGFR‐TKIs: A phase II, single‐arm trial

Junling Li, Yan Wang, Yalei Wang, 2018, Thoracic cancer.

Safety, tolerability, and pharmacokinetics of simotinib, a novel specific EGFR tyrosine kinase inhibitor, in patients with advanced non-small cell lung cancer: results of a phase Ib trial

Yuankai Shi, Ning Li, Sheng Yang, 2019, Cancer management and research.

Efficacy of icotinib in lung squamous‐cell cancer: A real‐world experience from single institution

Yuankai Shi, Jian-ping Xu, Xiaoyan Liu, 2017, Asia-Pacific journal of clinical oncology.

Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study

Yuankai Shi, Jian-ping Xu, Xiaoyan Liu, 2017, OncoTargets and therapy.

Tracking longitudinal genetic changes of circulating tumor DNA (ctDNA) in advanced Lung adenocarcinoma treated with chemotherapy

Yuankai Shi, Jian-liang Yang, Sheng Yang, 2019, Journal of Translational Medicine.

Suitability of Surgical Tumor Tissues, Biopsy, or Cytology Samples for Epidermal Growth Factor Receptor Mutation Testing in Non–Small Cell Lung Carcinoma Based on Chinese Population

Yuankai Shi, Sheng Yang, Yan Sun, 2014, Translational oncology.

191例EGFR突变状态不明晚期肺腺癌患者EGFR-TKIs耐药后化疗的疗效分析

P. He, Junling Li, Yuankai Shi, 2013, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

First-in-human phase I study of BPI-9016M, a dual MET/Axl inhibitor, in patients with non-small cell lung cancer

Yuankai Shi, X. Hao, P. Hu, 2020, Journal of Hematology & Oncology.

MiR-490-3p Inhibits the Malignant Progression of Lung Adenocarcinoma

Sheng Yang, Danfeng Jiang, Zhi-yang Li, 2020, Cancer management and research.

Immune checkpoint inhibitors combined with angiogenic inhibitors in the treatment of locally advanced or metastatic lung adenocarcinoma patients

Sheng Yang, Yu-tao Liu, Lin Lin, 2022, Cancer Immunology, Immunotherapy.

Low CCL19 expression is associated with adverse clinical outcomes for follicular lymphoma patients treated with chemoimmunotherapy

N. Lou, P. Liu, Yuankai Shi, 2021, Journal of Translational Medicine.

Low CCL19 Expression Is Associated With Adverse Clinical Outcomes For Patients With Advanced Stage Follicular Lymphoma

N. Lou, P. Liu, Yuankai Shi, 2021 .

Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study.

Peng Liu, Haifeng Song, Yuankai Shi, 2020, European journal of cancer.

Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma

Yuankai Shi, Jian-ping Xu, Xiaoyan Liu, 2016, OncoTargets and therapy.

Chinese a Nti鄄 Cancer a Ssociation

Feng, P. Liu, P. Liu, 2022 .

Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients

P. Xing, Yuankai Shi, Dan Wang, 2020, Theranostics.

Clinical response to apatinib monotherapy in advanced non‐small cell lung cancer

Yuankai Shi, Xiaoyan Liu, Sheng Yang, 2018, Asia-Pacific journal of clinical oncology.

Apatinib monotherapy or combination therapy for non-small cell lung cancer patients with brain metastases.

Jian-ping Xu, Xiaoyan Liu, Sheng Yang, 2020, Oncology research.

Penpulimab plus anlotinib as second-line treatment for the small cell lung cancer after failure of platinum-based systemic chemotherapy.

Yuankai Shi, Jun Zhao, C. Bai, 2021, Journal of Clinical Oncology.

The prognostic utility and the association of serum light chains (free and total) and absolute lymphocyte count in patients with newly diagnosed diffuse large B-cell lymphoma.

Peng Liu, Yuankai Shi, Jian-liang Yang, 2014, Leukemia research.

Genomic Alterations and MYD88MUT Variant Mapping in Patients with Diffuse Large B-Cell Lymphoma and Response to Ibrutinib

Peng Liu, Yuankai Shi, Biao Liu, 2020, Targeted Oncology.

Dismal outcome of relapsed or primary refractory adult T‐cell lymphoblastic lymphoma: A retrospective study from China

P. Liu, Yuankai Shi, Jian-liang Yang, 2021, Asia-Pacific journal of clinical oncology.

Predictive factors for inadequate stem cell mobilization in Chinese patients with NHL and HL: 14‐year experience of a single‐center study

P. Liu, Yuankai Shi, Lingdi Zhao, 2012, Journal of clinical apheresis.

Genetic Profiling of Diffuse Large B-Cell Lymphoma: A Comparison Between Double-Expressor Lymphoma and Non-Double-Expressor Lymphoma

P. Liu, Jian-liang Yang, Sheng Yang, 2022, Molecular Diagnosis & Therapy.

Development and validation of a novel risk stratification model and a survival rate calculator for diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study

Jian-liang Yang, Shengyu Zhou, Q. Zhong, 2023, Annals of hematology.

Ifosfamide, Cisplatin or Carboplatin, and Etoposide (ICE)-based Chemotherapy for Mobilization of Autologous Peripheral Blood Stem Cells in Patients with Lymphomas

P. Liu, Yuankai Shi, Sheng Yang, 2015, Chinese medical journal.

Intensity-modulated radiation therapy followed by GDP chemotherapy for newly diagnosed stage I/II extranodal natural killer/T cell lymphoma, nasal type

P. Liu, P. Xing, Yuankai Shi, 2017, Annals of Hematology.

GDP (Gemcitabine, Dexamethasone, and Cisplatin) Is Highly Effective and Well-Tolerated for Newly Diagnosed Stage IV and Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma, Nasal Type

P. Liu, Yuankai Shi, Ye-Xiong Li, 2016, Medicine.

A pilot study of the safety and efficacy of dexamethasone, ifosfamide, methotrexate and gemcitabine chemotherapy for natural killer/T-cell lymphoma

Yuankai Shi, Jian-liang Yang, Sheng Yang, 2015, Leukemia & lymphoma.

Gemcitabine, dexamethasone, and cisplatin (GDP) as salvage chemotherapy for patients with relapsed or refractory peripheral T cell lymphoma—not otherwise specified

P. Liu, Yuankai Shi, Weihu Wang, 2017, Annals of Hematology.

Comparison of gemcitabin, cisplatin, and dexamethasone (GDP), CHOP, and CHOPE in the first-line treatment of peripheral T-cell lymphomas

P. Liu, P. Xing, Yuankai Shi, 2016, Hematology.

Gemcitabine-based combination regimen in patients with peripheral T-cell lymphoma

P. Liu, Yuankai Shi, Jian-liang Yang, 2013, Medical Oncology.

Addition of rituximab is not associated with survival benefit compared with CHOP alone for patients with stage I diffuse large B-cell lymphoma.

P. Liu, Yuankai Shi, Weihu Wang, 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

High-dose therapy and autologous stem cell transplantation in peripheral T-cell lymphoma: treatment outcome and prognostic factor analysis

P. Liu, Yuankai Shi, Sheng Yang, 2013, International Journal of Hematology.

Development and validation of an ultrafiltration-UPLC-MS/MS method for rapid quantification of unbound docetaxel in human plasma.

Yuankai Shi, Ning Li, Sheng Yang, 2014, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Development and validation of a rapid and sensitive UPLC-MS/MS method for determination of total docetaxel from a lipid microsphere formulation in human plasma.

Yuankai Shi, Ning Li, Sheng Yang, 2013, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Characteristics and Management of TP53-Mutated Diffuse Large B-Cell Lymphoma Patients

Yuankai Shi, P. Liu, Jian-liang Yang, 2020, Cancer management and research.

CMAR_A_269624 11515..11522

P. Liu, Jian-liang Yang, Sheng Yang, 2020 .

Autologous hematopoietic stem cell transplantation in chemotherapy-sensitive lymphoblastic lymphoma: treatment outcome and prognostic factor analysis.

Guan-qing Wu, P. Liu, Yuankai Shi, 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

The clinical features, treatment, and prognostic factors for peripheral T‐cell lymphomas: A single‐institution analysis of 240 Chinese patients

P. Liu, Jian-liang Yang, Sheng Yang, 2022, Asia-Pacific journal of clinical oncology.

Long‐term survival and prognostic analysis of advanced stage follicular lymphoma in the rituximab era: A China single‐center retrospective study

Yuankai Shi, P. Liu, Jian-liang Yang, 2020, Asia-Pacific journal of clinical oncology.

Efficacy and safety of the combination of paclitaxel and platinum in advanced thymic carcinoma

Yuankai Shi, X. Hao, Xiang-ru Zhang, 2015, Thoracic cancer.

Icotinib as initial treatment in lung adenocarcinoma patients with brain metastases

Yuankai Shi, Jian-ping Xu, Xiaoyan Liu, 2016, Thoracic cancer.

Oncotargets and Therapy Dovepress Dovepress Efficacy and Safety of Icotinib in Patients with Brain Metastases from Lung Adenocarcinoma

Yuankai Shi, Xiaoyan Liu, Xiang-ru Zhang, 2022 .

Current management of chemotherapy-induced neutropenia in adults: key points and new challenges

H. Yao, Ying Cheng, Bing-he Xu, 2020, Cancer biology & medicine.

Aurora-A as an independent molecular prognostic marker in gastric cancer.

Yuankai Shi, Jing Wang, Yan Song, 2011, Oncology reports.

Phase I dose-finding study of sorafenib with FOLFOX4 as first-line treatment in patients with unresectable locally advanced or metastatic gastric cancer.

Yuankai Shi, Y. Chi, Jian-liang Yang, 2015, Chinese journal of cancer research = Chung-kuo yen cheng yen chiu.

吉非替尼治疗32例肺腺癌脑转移的临床经验

Yuankai Shi, Jian-ping Xu, Xiaoyan Liu, 2015, Zhongguo fei ai za zhi = Chinese journal of lung cancer.

Development and validation of a UPLC–MS/MS assay for the quantification of simotinib in human plasma

Yuankai Shi, Ning Li, Sheng Yang, 2014, Analytical and Bioanalytical Chemistry.

Comprehensive Profiling of Gene Copy Number Alterations Predicts Patient Prognosis in Resected Stages I–III Lung Adenocarcinoma

D. Lin, P. Xing, Junling Li, 2019, Front. Oncol..

Evaluating stress, satisfaction and the associated influencing factors of participants in cancer clinical trials: a cross-sectional study in China

P. Liu, P. Xing, Jian-liang Yang, 2019, BMJ Open.

Chinese a Nti鄄 Cancer a Ssociation

P. Liu, Yuankai Shi, L. Xue, 2022 .

Comparison of CBV, BEAM and BEAC high‐dose chemotherapy followed by autologous hematopoietic stem cell transplantation in non‐Hodgkin lymphoma: Efficacy and toxicity

P. Liu, Yuankai Shi, Jian-liang Yang, 2017, Asia-Pacific journal of clinical oncology.

Multi-omics analysis and response prediction of PD-1 monoclonal antibody containing regimens in patients with relapsed/refractory diffuse large B-cell lymphoma

Liling Huang, Yuankai Shi, Sheng Yang, 2024, Cancer immunology, immunotherapy : CII.

Primary breast diffuse large B‐cell lymphoma in the rituximab era: Therapeutic strategies and patterns of failure

Yu Zhao, Yuankai Shi, Aichun Liu, 2018, Cancer science.